Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent clostridioides difficile infection - Khanna, S; Assi, M; Lee, C (Drugs, 2022)
et al.